The merits of action of interferon α in chronic myelogenous leukaemia

W. E. Aulitzky; C. Peschel; F. Schneller; C. Huber

The merits of action of interferon α in chronic myelogenous leukaemia

W. E. Aulitzky, C. Peschel, F. Schneller, C. Huber

University Medical Center

Research output: Contribution to journal › Review article › peer-review

Abstract

Interferon (IFN) has become a standard for treatment of chronic phase chronic myelogenous leukaemia (CML). Randomised clinical trials have shown improved long term survival in patients treated with IFN-α compared to hydroxyurea or busulfan. However, the critical mechanisms of IFN action are not clear. Both direct and indirect antiproliferative effects might play a role for the beneficial effects of IFN treatment. This review briefly summarises the current knowledge on the pathogenesis of CML, the potential beneficial mechanisms of IFN action and the results of clinical studies of IFN in CML.

Original language	English
Pages (from-to)	NIL.0001-338
Journal	FORUM - Trends in Experimental and Clinical Medicine
Volume	5
Issue number	4
State	Published - 1995
Externally published	Yes

Keywords

BMT
Chronic myelogenous leukaemia
IFN-α
Ph-chromosome

Cite this

@article{08e8689fb0884d9e9431de9dd44e2ccf,

title = "The merits of action of interferon α in chronic myelogenous leukaemia",

abstract = "Interferon (IFN) has become a standard for treatment of chronic phase chronic myelogenous leukaemia (CML). Randomised clinical trials have shown improved long term survival in patients treated with IFN-α compared to hydroxyurea or busulfan. However, the critical mechanisms of IFN action are not clear. Both direct and indirect antiproliferative effects might play a role for the beneficial effects of IFN treatment. This review briefly summarises the current knowledge on the pathogenesis of CML, the potential beneficial mechanisms of IFN action and the results of clinical studies of IFN in CML.",

keywords = "BMT, Chronic myelogenous leukaemia, IFN-α, Ph-chromosome",

author = "Aulitzky, {W. E.} and C. Peschel and F. Schneller and C. Huber",

year = "1995",

language = "English",

volume = "5",

pages = "NIL.0001--338",

journal = "FORUM - Trends in Experimental and Clinical Medicine",

issn = "1121-8142",

publisher = "Scuola superiore di oncologia e scienze biomediche",

number = "4",

}

TY - JOUR

T1 - The merits of action of interferon α in chronic myelogenous leukaemia

AU - Aulitzky, W. E.

AU - Peschel, C.

AU - Schneller, F.

AU - Huber, C.

PY - 1995

Y1 - 1995

N2 - Interferon (IFN) has become a standard for treatment of chronic phase chronic myelogenous leukaemia (CML). Randomised clinical trials have shown improved long term survival in patients treated with IFN-α compared to hydroxyurea or busulfan. However, the critical mechanisms of IFN action are not clear. Both direct and indirect antiproliferative effects might play a role for the beneficial effects of IFN treatment. This review briefly summarises the current knowledge on the pathogenesis of CML, the potential beneficial mechanisms of IFN action and the results of clinical studies of IFN in CML.

AB - Interferon (IFN) has become a standard for treatment of chronic phase chronic myelogenous leukaemia (CML). Randomised clinical trials have shown improved long term survival in patients treated with IFN-α compared to hydroxyurea or busulfan. However, the critical mechanisms of IFN action are not clear. Both direct and indirect antiproliferative effects might play a role for the beneficial effects of IFN treatment. This review briefly summarises the current knowledge on the pathogenesis of CML, the potential beneficial mechanisms of IFN action and the results of clinical studies of IFN in CML.

KW - BMT

KW - Chronic myelogenous leukaemia

KW - IFN-α

KW - Ph-chromosome

UR - http://www.scopus.com/inward/record.url?scp=0028845847&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0028845847

SN - 1121-8142

VL - 5

SP - NIL.0001-338

JO - FORUM - Trends in Experimental and Clinical Medicine

JF - FORUM - Trends in Experimental and Clinical Medicine

IS - 4

ER -

The merits of action of interferon α in chronic myelogenous leukaemia

Abstract

Keywords

Other files and links

Fingerprint

Cite this